Ibrutinib, a BTK inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

Publication date: Available online 4 April 2017
Source:Journal of Allergy and Clinical Immunology
Author(s): Jennifer A. Regan, Yun Cao, Melanie C. Dispenza, Shuo Ma, Leo I. Gordon, Adam M. Petrich, Bruce S. Bochner

Teaser

Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was shown to eliminate skin test reactivity in vivo and IgE-dependent basophil activation testing ex vivo. Blockade of the BTK pathway may represent a novel therapeutic strategy for the effective reduction of allergic reactivity.


http://ift.tt/2oHUhR2